Render Target: STATIC
Render Timestamp: 2024-11-22T12:07:00.075Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-08-01 15:29:30.086
Product last modified at: 2024-05-30T07:10:28.346Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

VEGF-A Antibody #65373

We recommend the following alternatives

Filter:
  • WB

Inquiry Info. # 65373

Please see our recommended alternatives.

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 16, 20, 23, 26
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    VEGF-A Antibody recognizes endogenous levels of all isoforms of total VEGF-A protein. This antibody also detects a 47 kDa band of unknown origin.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His38 of human VEGF-A protein. Antibodies are purified by peptide affinity chromatography.

    Background

    Vascular endothelial growth factor-A (VEGF-A; formerly VEGF) belongs to the VEGF/PDGF family of growth factors that play a critical role in promoting vascular development. VEGF-A is primarily known for its function in promoting angiogenesis, the process by which new blood vessels are sprouted from pre-existing blood vessels. VEGF-A has eight isoforms, derived from differentially spliced mRNA variants encoded by the VEGF-A gene (1). All isoforms contain a conserved receptor binding domain, but differ in their C-terminal domains that regulate binding to components in the extracellular matrix. VEGF-A is secreted by multiple cell types, including fibroblasts, macrophages, and some tumor cells (1). Binding of VEGF-A to its cognate receptors (VEGFR2 and to a lesser extent VEGFR1) on the endothelial cell surface activates the receptor and initiates downstream signaling, resulting in endothelial cell proliferation, survival, migration, and changes to vascular permeability, all crucial processes for angiogenesis (3). Tumor cells have been shown to respond to hypoxia by increasing VEGF-A mRNA expression. Increased secretion of VEGF-A in the tumor microenvironment stimulates angiogenesis to further promote tumor progression (4). In addition to promoting tumor angiogenesis, VEGF-A has also been shown to play an important role in normal tissue development, tissue regeneration, tumor cell proliferation, neovascular eye diseases, and cancer immunity (2,5). For this reason, targeting angiogenesis via the VEGF-A pathway has been a major focus in cancer therapeutics research.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.